Fluoxetine HCl
For research use only.
Catalog No.S1333 Synonyms: Lilly110140
10 publications
Molecular Weight(MW): 345.79
Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.
3 Customer Reviews
-
The SWIP phenotype in hlh-17(ns204) animals is unaffected by pretreatment with fluoxetine (C). In all panels, n = 30 animals/rep/strain; dark bars = minus inhibitor; and light bars = plus inhibitor. *P< 0.05; **P<0.005; ***P<0.0005.
G3 (Bethesda), 2014, 4(6):1081-9.. Fluoxetine HCl purchased from Selleck.
Representative photomicrographs of PI-positive neural cells in different groups at 24 h after SAH (n = 3/group). Fluorescence colors: DAPI: blue and PI: red. Scale bar = 100 μm.
J Neuroinflammation, 2017, 14(1):186. Fluoxetine HCl purchased from Selleck.
-
Immunofluorescence test confirmed the activation of microglia with higher level of TNFα expression. Ipt and Flu treatment clearly reversed the all significant changes to normal levels. White arrows indicate TNFα, CD11b and Hoechst co-located.
Brain Res Bull, 2017, 130:146-155. Fluoxetine HCl purchased from Selleck.
Purity & Quality Control
Choose Selective 5-HT Receptor Inhibitors
Biological Activity
| Description | Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell. [1] Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex. [2] Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus. [3] Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration. [4] |
|
| In vivo | Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague–Dawley rats. [1] Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone. [5] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 69 mg/mL (199.54 mM) |
|---|---|---|
| Ethanol | 69 mg/mL (199.54 mM) | |
| Water | 4 mg/mL (11.56 mM) |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 345.79 |
|---|---|
| Formula | C17H18F3NO.HCl |
| CAS No. | 56296-78-7 |
| Storage |
powder in solvent |
| Synonyms | Lilly110140 |
| Smiles | Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2 |
In vivo Formulation Calculator (Clear solution)
| Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment) | ||||||||||
| Dosage | mg/kg |  |
Average weight of animals | g | |
Dosing volume per animal | ul | |
Number of animals | |
| Step 2: Enter the in vivo formulation () | ||||||||||
| % DMSO % % Tween 80 % ddH2O | ||||||||||
| CalculateReset | ||||||||||
Calculation results:
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT01615055 | Withdrawn | Drug: Fluoxetine|Other: Placebo | Cognitive Dysfunction | University of California Los Angeles|City of Hope Medical Center | June 2018 | Early Phase 1 |
| NCT03390933 | Recruiting | Drug: Fluoxetine | Depression|Hemodialysis-Induced Symptom | MetroHealth Medical Center | March 1 2018 | Phase 4 |
| NCT02767999 | Recruiting | Drug: Fluoxetine|Drug: Placebo|Radiation: fMRI | Stroke | University Hospital Toulouse | February 27 2017 | Phase 4 |
| NCT03476525 | Recruiting | Drug: Fluoxetine | Obesity Morbid | Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital | November 2 2016 | -- |
| NCT02063425 | Terminated | Drug: Fluoxetine|Drug: Placebo of fluoxetine | Cerebral Infarction | Centre Hospitalier St Anne | February 2014 | Not Applicable |
| NCT01967979 | Completed | Drug: RO5285119|Drug: fluoxetine|Drug: itraconazole | Healthy Volunteer | Hoffmann-La Roche | October 2013 | Phase 1 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
